Welcome to our dedicated page for Cartesian Therapeutics news (Ticker: RNAC), a resource for investors and traders seeking the latest updates and insights on Cartesian Therapeutics stock.
Cartesian Therapeutics, Inc. reports news on its late clinical-stage biotechnology work in mRNA-engineered cell therapy for autoimmune diseases. The company's lead asset, Descartes-08, is an autologous BCMA-targeting CAR-T candidate being developed for generalized myasthenia gravis, myositis indications such as dermatomyositis and antisynthetase syndrome, and pediatric autoimmune diseases including juvenile dermatomyositis.
Recurring updates cover clinical program progress across AURORA, TRITON and HELIOS, FDA designations for Descartes-08, financial results and cash runway commentary, corporate presentations and investor conference participation. News also includes Nasdaq employment inducement grants, equity incentive plan activity, and board or committee changes tied to the company's public-company governance.
Cartesian Therapeutics (NASDAQ: RNAC) reported Q1 2026 results and pipeline updates. Cash, cash equivalents and restricted cash were $120.4 million as of March 31, 2026, after raising $14.6 million via its ATM program, expected to fund operations into mid-2027, including completion of the Phase 3 AURORA trial.
Clinical progress: enrollment continues in the randomized Phase 3 AURORA trial (~100 AChR Ab+ MG patients), Phase 2 TRITON in dermatomyositis/antisynthetase syndrome initiated, and multiple patients enrolled in the Phase 1/2 HELIOS pediatric trial (JDM); Descartes-08 has FDA Rare Pediatric Disease Designation for JDM. Q1 R&D was $19.5M, G&A $7.1M, and net loss was $39.2M (net loss per share $1.46).
Cartesian Therapeutics (NASDAQ: RNAC) granted inducement stock options to two new employees on April 1, 2026. The awards total 52,450 options with an exercise price of $6.39, equal to the closing Nasdaq price that day. Options vest 25% on April 1, 2027, then monthly over 36 months, fully vesting April 1, 2030, and carry a ten-year term. Grants were approved by the board and made under the company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan pursuant to Nasdaq Rule 5635(c)(4).
Cartesian Therapeutics (NASDAQ: RNAC) reported full-year 2025 results and a corporate update. Key points: $126.9M cash as of Dec 31, 2025, runway into mid-2027; ongoing Phase 3 AURORA enrollment (~100 patients); FDA-accepted IND for Phase 2 TRITON in myositis (initiate 1H26); active Phase 1/2 HELIOS pediatric trial; Nature Medicine publications showing 12-month durable responses.
2025 R&D $58.0M, G&A $31.5M, net loss $130.3M ($5.02/share).
Cartesian Therapeutics (NASDAQ: RNAC) said management will participate in investor conferences in March and April 2026, including a presentation at the 46th Annual TD Cowen Health Care Conference and fireside chats at Leerink and Needham.
Live webcasts and archived replays will be accessible in the Events section of the company website for a limited time.
Cartesian Therapeutics (NASDAQ: RNAC) granted inducement stock options to two new employees on February 2, 2026. The awards total 12,050 options with an exercise price of $6.79 per share, equal to the Nasdaq closing price that day.
The options vest 25% on February 2, 2027, then monthly over 36 months, fully vesting February 2, 2030, and carry a ten-year term. Grants were approved by the board and made under Nasdaq Rule 5635(c)(4) as inducements to employment.
Cartesian Therapeutics (NASDAQ: RNAC) reported progress on Descartes-08 and 2026 priorities. Enrollment is on track in the randomized, double-blind Phase 3 AURORA trial (~100 AChR Ab+ MG participants) using six once-weekly outpatient infusions without preconditioning; primary endpoint is ≥3-point MG-ADL improvement at Month 4. The FDA accepted an IND for a seamless adaptive Phase 2 myositis trial (TRITON) up to 50 participants with an interim analysis after 10 participants to inform a potential single pivotal trial in 1H26. A Phase 1/2 pediatric trial (HELIOS) in juvenile dermatomyositis has been initiated. Peer-reviewed Nature Medicine publications describe mechanism of action and 12-month durable responses; a biologic-naive subgroup (n=7) showed 57% minimal symptom expression at Month 6 sustained to Month 12 and a median prednisone dose reduction of 55% at Month 12. No CRS or ICANS reported. Cash runway is expected into mid-2027.
Cartesian Therapeutics (NASDAQ: RNAC) announced inducement stock option awards to two new employees granted on January 2, 2026. The company issued options to purchase an aggregate of 7,350 shares at an exercise price of $6.76, equal to the Nasdaq closing price on the grant date.
The options were granted under the company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan, approved by the board, vest 25% on January 2, 2027 and then in 36 equal monthly installments, fully vesting on January 2, 2030, and have a ten-year term. Grants were made under Rule 5635(c)(4) of the Nasdaq Listing Rules.
Cartesian Therapeutics (NASDAQ: RNAC) announced the appointment of Adrian Bot, M.D., Ph.D. to its Board of Directors effective Dec. 18, 2025. Dr. Bot brings three decades of R&D experience in immune, cell, gene therapy and nanomedicines and will serve on the Board's Science and Technology Committee.
His background includes senior R&D roles at Capstan, Kite/Gilead, MannKind and Alliance Pharma, involvement with first-in-class CAR T development, and leadership in RNA-based precision medicines; he has co-authored >200 peer-reviewed works.
Cartesian Therapeutics (NASDAQ: RNAC) reported initial Phase 2 results for Descartes-08 in SLE showing a 100% LLDAS response at Month 3 among participants who reached that visit (n=3) and 2 of 3 DORIS remissions. Descartes-08 was well tolerated in the outpatient setting with no CRS or ICANS reported and statistically significant reductions (p<0.01) in several proinflammatory cytokines and plasmacytoid dendritic cells. The company will pause further SLE enrollment to prioritize Phase 3 myasthenia gravis and a planned seamless adaptive Phase 2-to-pivotal trial in myositis expected to start in 1H 2026, with an IND filing planned by end of 2025. Cash runway is expected to support operations through mid-2027.
Cartesian Therapeutics (NASDAQ: RNAC) reported Q3 2025 results and clinical updates on Nov 6, 2025. The company reported $145.1 million in cash, cash equivalents and restricted cash as of Sept 30, 2025, which it expects will support operations into mid-2027, including completion of the Phase 3 AURORA trial.
Clinical highlights: enrollment is on track in the randomized Phase 3 AURORA trial of Descartes-08 in acetylcholine receptor antibody-positive myasthenia gravis (~100 participants; primary endpoint: ≥3-point MG-ADL improvement at Month 4), preliminary Phase 2 Descartes-08 SLE data expected by year-end, and a pediatric basket Phase 2 trial initiation expected by year-end; FDA granted Rare Pediatric Disease Designation for Descartes-08 in juvenile dermatomyositis. Descartes-15 Phase 1 in multiple myeloma remains ongoing.
Financials: R&D $13.8M, G&A $7.7M for Q3 2025; net loss $35.9M, or $1.38 per share, vs. net loss $24.2M, or $1.13 per share in Q3 2024.